News Release

Antenatal HIV

Peer-Reviewed Publication

BMC (BioMed Central)

South Africa's Prevention of Mother to Child Transmission (PMTCT) Programme has severe shortcomings that could be doing more harm than good. HIV patients are missing out on opportunities to receive a key intervention namely the nevirapine tablet according to a study published in the online open access journal AIDS Research and Therapy.

Lungiswa Nkonki, of the Medical Research Council, Tygerberg, South Africa, worked with colleagues from University of the Western Cape (UWC), Health Systems Trust and the Tulane School of Public Health and Tropical Medicine, New Orleans, USA, on the study. The study's qualitative research with women who had participated in the public sector PMTCT programme revealed critical failures, not only in testing expectant mothers for HIV and giving them the results of the test, but also in a lack of intervention to help protect the unborn child from infection. A 50% reduction in transmission of HIV from mother to child is possible with the use of the drug, nevirapine, but this is not being administered routinely.

The research team interviewed 58 HIV-positive women in South Africa and collected detailed information about their experiences of antenatal care. They also investigated whether or not there were missed opportunities for participation in prevention of mother-to-child transmission programs.

Fifteen of the interviewees missed out on nevirapine, not because of the stigma associated with HIV/AIDS, nor ignorance, but because of health systems failures, say the researchers. Of the 15 women, six women were not tested for HIV during antenatal care. Two who were tested received no results and seven were tested and received results but did not receive Nevirapine.

"Health Systems failures within these programme ranged from non-availability of counsellors, supplies such as HIV test kits, consent forms, health staff giving the women incorrect instructions about when to take the tablet and health staff not supplying the women with the tablet to take," the researchers say.

Nkonki and colleagues make two simple suggestions. First, HIV testing should be strengthened to enable access to preventative interventions. Secondly, a combination of two or three antiretroviral drugs starting during pregnancy and continuing for one week after delivery should replace the single dose regimen to improve uptake as recommended by the World Health Organisation (WHO).

###

Article: Missed opportunities for participation in prevention of mother to child transmission programmes: simplicity of nevirapine does not necessarily lead to optimal uptake. A qualitative study.
Lungiswa L Nkonki, Tanya M Doherty, Zelee Hill, Mickey Chopra, Nikki Schaay and Carl Kendall
AIDS Research and Therapy (in press)

During embargo, article available at: http://www.aidsrestherapy.com/imedia/1839918249149728_article.pdf?random=175099

After the embargo, article available from the journal website at: http://www.aidsrestherapy.com/

Article citation and URL available on request at press@biomedcentral.com on the day of publication

Please quote the journal in any story you write. If you are writing for the web, please link to the article. All articles are available free of charge, according to BioMed Central's Open Access policy.

To speak with the author, please contact Julian Jacobs (Press Office, Medical Research Council), e-mail: julian.jacobs@mrc.ac.za, telephone: +27 21 938 0241

AIDS Research and Therapy is an open access, online journal that publishes peer-reviewed research articles from scientists working to prevent the spread of AIDS. AIDS Research and Therapy aims to publish basic science as well as clinically important research articles that impact on abating the spread of AIDS. This multidisciplinary journal aims to keep scientists and clinicians abreast of the latest research on HIV-1.

BioMed Central (http://www.biomedcentral.com) is a UK-based independent online publishing house committed to providing open access to peer-reviewed biological and medical research. This commitment is based on the view that immediate free access to research and the ability to freely archive and reuse published information is essential to the rapid and efficient communication of science.

BioMed Central currently publishes over 160 journals across biology and medicine. In addition to open-access original research, BioMed Central also publishes reviews, commentaries and other non-original-research content. Depending on the policies of the individual journal, this content may be open access or provided only to subscribers.


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.